Exploring the use of the medicinal leech: A clinical risk-benefit analysis

被引:103
|
作者
deChalain, TMB [1 ]
机构
[1] EMORY UNIV,DEPT PLAST SURG,ATLANTA,GA 30322
关键词
D O I
10.1055/s-2007-1006471
中图分类号
R61 [外科手术学];
学科分类号
摘要
The medicinal leech, Hirudo medicinalis, has been used with increasing frequency for salvage of compromised pedicled flaps and microvascular free-tissue transfers. The data pertaining to 18 cases in which flap salvage with leeches was attempted were reviewed and contrasted with the data from 108 published cases from other centers. A further analysis isolated and examined 19 cases in which infection, secondary to leech utilization, supervened. Results suggested that successful salvage of tissue with leeches occurs in 70 to 80 percent of cases. In contrast, the infection rate of most series is between 7 and 20 percent and, when a clinically significant infection occurs, the flap salvage rate drops to 30 percent or less. In addition to infection, the risks of leech therapy include blood loss, which may require replacement transfusion, loss of leeches into body orifices and spaces, allergic reactions, and adverse psychological responses. Clinical indications and contraindications, and strategies to reduce the risks of leech usage, are discussed. Conclusions are that leeches are best used early, and in accordance with an accepted institutional protocol. For each case, the potential risks and benefits must be rigorously assessed and honestly applied.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 50 条
  • [31] BRAFO -: Risk-benefit analysis of foods
    Boobis, Alan
    Contor, Laura
    Kind, Paul
    Mueller, Detlef
    Rechkemmer, Gerhard
    Verhagen, Hans
    Szoradi, Andras
    ANNALS OF NUTRITION AND METABOLISM, 2007, 51 : 393 - 394
  • [32] Labour analgesia - A risk-benefit analysis
    Eberle, RL
    Norris, MC
    DRUG SAFETY, 1996, 14 (04) : 239 - 251
  • [33] ADVICE AND CONSENT + RISK-BENEFIT ANALYSIS
    BONINE, JE
    ATLANTIC, 1979, 243 (05): : 31 - 31
  • [34] Basic aspects of risk-benefit analysis
    Beckmann, J
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1999, 25 (01): : 89 - 95
  • [35] Quantitative risk-benefit analysis of natalizumab
    Thompson, J. P.
    Noyes, K.
    Dorsey, E. R.
    Schwid, S. R.
    Holloway, R. G.
    NEUROLOGY, 2008, 71 (05) : 357 - 364
  • [36] Hormones and cancer: Risk-benefit analysis
    Sevelda, P
    Salzer, H
    GYNAKOLOGISCH-GEBURTSHILFLICHE RUNDSCHAU, 1998, 38 (02): : 61 - 63
  • [37] QUANTITATIVE RISK-BENEFIT ANALYSIS OF NATALIZUMAB
    Steiner, Israel
    NEUROLOGY, 2009, 72 (20) : 1791 - 1791
  • [38] Risk-benefit analysis of fish consumption
    Leblanc, Jean-Charles
    Sirot, Veronique
    Volatier, Jean-Luc
    CAHIERS DE NUTRITION ET DE DIETETIQUE, 2009, 44 (04): : 182 - 188
  • [39] A Risk-Benefit Analysis Is Coffee healthy?
    Richling, Elke
    Habermeyer, Michael
    CHEMIE IN UNSERER ZEIT, 2014, 48 (01) : 12 - 20
  • [40] A RISK-BENEFIT ANALYSIS FOR THE TREATMENT OF HYPERTENSION
    BULPITT, CJ
    POSTGRADUATE MEDICAL JOURNAL, 1993, 69 (816) : 764 - 774